12-year positive survival data for BSD's hyperthermia therapy:
This article was originally published in Clinica
A 12-year follow-up study has shown positive survival rates for BSD Medical's precision-focused hyperthermia therapy device, BSD-2000, when used as an enhancement to radiotherapy. The 358-patient study assessed patients with locally-advanced pelvic tumours, and many had extremely poor prognoses. The follow-up found that patients who received radiation plus hyperthermia therapy had a survival rate of 37%, compared with 20% for those receiving radiation alone. Furthermore, the margin of increased survival rate of patients was similar at 12 years (an 85% increase) as at 3 years (an 89% increase). One of the primary concerns about new therapies is their durability, said Salt Lake City, Utah-based BSD. The findings were presented at the European Society for Hyperthermic Oncology, in Prague, Czech Republic, in June.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.